title: Lymphoma incidence, survival and prevalence 2004-2014: sub-type analyses from the UK's Haematological Malignancy Research Network.
abstract: BACKGROUND
  Population-based information about cancer occurrence and survival are required to inform clinical practice and research; but for most lymphomas data are lacking.
  
  
  METHODS
  Set within a socio-demographically representative UK population of nearly 4 million, lymphoma data (N=5796) are from an established patient cohort.
  
  
  RESULTS
  Incidence, survival (overall and relative) and prevalence estimates for >20 subtypes are presented. With few exceptions, males tended to be diagnosed at younger ages and have significantly (P<0.05) higher incidence rates. Differences were greatest at younger ages: the <15 year male/female rate ratio for all subtypes combined being 2.2 (95% CI 1.3-3.4). These gender differences impacted on prevalence; most subtype estimates being significantly (P<0.05) higher in males than females. Outcome varied widely by subtype; survival of patients with nodular lymphocyte predominant Hodgkin lymphoma approached that of the general population, whereas less than a third of those with other B-cell (e.g., mantle cell) or T-cell (e.g., peripheral-T) lymphomas survived for ≥5 years. No males/female survival differences were detected.
  
  
  CONCLUSIONS
  Major strengths of our study include completeness of ascertainment, world-class diagnostics and generalisability. The marked variations demonstrated confirm the requirement for 'real-world' data to inform aetiological hypotheses, health-care planning and the future monitoring of therapeutic changes.
authors: Epidemiology and Cancer Statistics Group, Department of Health Sciences, University of York, York, YO10 5DD, UK.
authors: A
authors: A
authors: Smith
authors: Epidemiology and Cancer Statistics Group, Department of Health Sciences, University of York, York, YO10 5DD, UK.
authors: S
authors: S
authors: Crouch
authors: Epidemiology and Cancer Statistics Group, Department of Health Sciences, University of York, York, YO10 5DD, UK.
authors: S
authors: S
authors: Lax
authors: Epidemiology and Cancer Statistics Group, Department of Health Sciences, University of York, York, YO10 5DD, UK.
authors: J
authors: J
authors: Li
authors: Epidemiology and Cancer Statistics Group, Department of Health Sciences, University of York, York, YO10 5DD, UK.
authors: D
authors: D
authors: Painter
authors: Epidemiology and Cancer Statistics Group, Department of Health Sciences, University of York, York, YO10 5DD, UK.
authors: D
authors: D
authors: Howell
authors: Queens Centre for Oncology, Castle Hill Hospital, Hull HU16 5JQ, UK.
authors: R
authors: R
authors: Patmore
authors: St James's Institute of Oncology, Leeds Teaching Hospitals NHS Trust, Leeds LS9 7TF, UK.
authors: A
authors: A
authors: Jack
authors: Epidemiology and Cancer Statistics Group, Department of Health Sciences, University of York, York, YO10 5DD, UK.
authors: E
authors: E
authors: Roman
mesh_terms: D000293:Adolescent; D000328:Adult; D000368:Aged; D002648:Child; D002675:Child, Preschool; D015331:Cohort Studies; D005260:Female; D005500:Follow-Up Studies; D019337:Hematologic Neoplasms / Q000453:epidemiology* / Q000401:mortality*; D006801:Humans; D015994:Incidence; D007223:Infant; D007231:Infant, Newborn; D008223:Lymphoma / Q000145:classification / Q000453:epidemiology* / Q000401:mortality*; D008297:Male; D008875:Middle Aged; D015995:Prevalence; D011379:Prognosis; D015996:Survival Rate; D006113:United Kingdom / Q000453:epidemiology; D055815:Young Adult